You searched for "implant"
Adjunct amniotic membrane during enucleation for retinoblastoma to prevent implant exposure
28 February 2025
| Fiona Rowe (Prof)
|
EYE - Paediatrics
Amniotic membrane (AM) has potential for treatment of retinoblastoma (RB) patients with contracted sockets after enucleation. The authors present their experience of AM with enucleation for patients with RB after chemotherapy in this retrospective study of 100 eyes of 107...
Intracameral sodium hyaluronate for postoperative hypotony after Baerveldt glaucoma implant
1 June 2019
| Ivan Yip
|
EYE - Glaucoma
This is a retrospective study to examine the effect of 0.1ml of sodium intracameral sodium hyaluronate 1.4% (Healon GV – HGV) in patients who had hypotony (IOP<5mmHg) within three months of having a Baerveldt glaucoma implant (BGI) operation. Hypotony is...
One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management
1 August 2018
| Sofia Rokerya
|
EYE - Glaucoma
The authors report a retrospective, non-randomised interventional case series of 39 patients who underwent a standalone XEN45 implantation. All 39 patients (female: male=1.2: 1) completed 12-month follow-up. Mean age was 70.1 years (range 32–92). Primary outcome measures were the intraocular...
Efficacy of intravitreal dexamethasone implant in patients with persistent macular oedema
1 December 2014
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Chronic cystoid macular oedema (CME) can develop secondary to various pathologies such as diabetic maculopathy, retinal vein occlusion and uveitis. It can cause significant visual impairment and macular damage. The therapeutic effect of corticosteroids in CME is through one or...
An unusual case of silicone oil in the anterior chamber simulating intraocular implant
Silicone oil internal tamponade has been used for over 50 years, even prior to pars plana vitrectomy [1].Over a course of time silicone oil may migrate to the anterior chamber through the pupil. This may disperse in the form of...
Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO
1 December 2021
| Jonathan Chan
|
EYE - Vitreo-Retinal
This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...
Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection
3 April 2023
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Dexamethasone implant, Diabetic macular edema, Pars plana vitrectomy, Posterior subtenon triamcinolone
This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...
Bovine pericardium scleral patch graft associated scleritis: Ahmed valve implant for pupillary block glaucoma
Processed bovine pericardium is a lyophilised collagen sheet used as a surgical armamentarium. It renders the material antigenically inert with minimal inflammation [1]. Sclera patch pericardium graft (Tutopatch) is a collagenous membrane derived from solvent preserved, irradiated bovine pericardium [2]...
Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant
This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative follow up
29 March 2023
|
glaucoma
Chavanod (near Annecy), France, March 29, 2023 - Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, announced the positive results of a 24-month post-operative follow-up on a clinical trial of CID, its first generation Cilio-scleral Inter-positioning Device.
Sight Sciences: The Role of Implant-Free MIGS in Glaucoma Care The OMNI® Surgical System
19 September 2024
18:30 Arrival, Refreshments and Dry-Lab Demonstrations 19:00 Targeting the iridocorneal angle with implant-free MIGS, Viscocanaloplasty and Trabeculotomy : C-109172 (1 CPD) Mr. Francesco Stringa (Moderator) Southampton University Hospital 19:45 Don’t miss the opportunity! Combining cataract surgery and MIGS : C-109173...
Sight Sciences: Early Intervention with Implant-Free MIGS. The OMNI Surgical System
11 January 2024
Agenda 18:30 Arrival & Refreshments19:00 Introductions & Welcome : Ms. Indira Madgula (Moderator), Royal Preston Hospital19:15 The Patients’ Perspective : Why MIGS, Why OMNI: Dr. Andrew Tatham, Princess Alexandra Eye Pavilion, Edinburgh19:45 Q&A - Discussion20:15 Close - Buffet Dinner
